c-JUN is a component of the heterodimeric AP-1 transcription factor, which is regarded as an oncoprotein, and promotes fibrosis in liver, skin, and lung; a c-JUN N-terminal kinase (JNK) inhibitor has been used in clinical trials for patients with pulmonary fibrosis (54–57). Here, MAPK8 is linked to pulmonary fibrosis.